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food additive
1  
EFSA Panel on Food additives and Nutrient Sources added to Food (ANS)
2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The Panel on Additives and Nutrient Sources added to Food (ANS) delivers an opinion re-evaluating the safety 
of an antioxidant 4-hexylresorcinol (4-HR) (E 586). The SCF in 2003 and the JECFA in 1996 recognised that 
available database was not sufficient to establish an ADI but considered 4-HR toxicologically acceptable for 
prevention of melanosis in shrimps provided residues in crustacean meat did not exceed 2 mg/kg (SCF) or 
1 mg/kg (JECFA). The Panel was not provided with a newly submitted dossier and no new toxicological or 
biological information was submitted for the present re-evaluation following a public call for data and based its 
evaluation on previous evaluations and additional literature that became available since then.  The Panel agreed 
with the SCF that the database did not allow the establishment of an ADI. The Panel considered nephropathy in 
mice as the most sensitive endpoint for 4-HR toxicity. The lowest BMDL10 for nephropathy in carcinogenicity 
study in mice (4 mg/kg bw/day) and the highest exposure estimate (3.3 µg/kg bw/day, adults, 95th percentile of 
consumers  only)  provided  the  MoS  considered  by  the  Panel  as  sufficient  given  the  conservative  nature  of 
exposure  estimates  and  limited  uses.  The  Panel  concluded  that  4-HR  was  toxicologically  acceptable  for 
prevention of melanosis in shrimps and related crustaceans provided that residues in crustacean meat do not 
exceed  2 mg/kg.  The  Panel  concluded  that  any  increase  in  the  permitted  use  would  require  additional 
reproductive toxicity studies. As the information on actual residual levels in crustaceans was limited the Panel 
recommended monitoring of these levels in the European market. 
© European Food Safety Authority, 2014 
KEY WORDS 
4-hexylresorcinol, E586, 4-hexyl-1,3benzenediol, 4-hexyl-1,3-dihydroxybenzene, CAS Registry Number 136-
77-6, food antioxidant, food additive 
                                                       
1  On request from the European Commission, Question No EFSA-Q-2011-00485, adopted on 02 April 2014. 
2  Panel  members:  Fernando  Aguilar,  Riccardo  Crebelli,  Birgit  Dusemund, Pierre Galtier, David Gott, Ursula Gundert-
Remy,  Jürgen  König,  Claude  Lambré,  Jean-Charles  Leblanc,  Alicja  Mortensen,  Pasquale  Mosesso,  Rose  Martin, 
Dominique Parent-Massin, Agneta Oskarsson, Ivan Stankovic, Paul Tobback, Ine Waalkens-Berendsen, Rudolf Antonius 
Woutersen, Matthew Wright. Correspondence: ans@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank the members of the Working Group B on Food Additives and Nutrient 
Sources added to Food: Fernando Aguilar, Polly Boon, Riccardo Crebelli, Birgit Dusemund, David Gott, Torben Hallas-
Møller, Jürgen König, Oliver Lindtner, Daniel Marzin, Alicja Mortensen, Agneta Oskarsson, Iona Pratt †, Paul Tobback, 
Ine Waalkens-Berendsen, Rudolf Antonius Woutersen for the preparatory work on this scientific opinion and EFSA staff: 
Anna Christodoulidou and Alexandra Tard for the support provided to this scientific opinion. 
†  Deceased. 
 Re-evaluation of 4-hexylresorcinol (E 586) as a food additive  
 
EFSA Journal 2014;12(4):3643  2 
SUMMARY 
Following  a  request  from  the  European  Commission,  the  Panel  on  Food  Additives  and  Nutrient 
Sources added to Food (ANS) was asked to deliver a scientific opinion on the re-evaluation of 4-
hexylresorcinol (4-HR) (E 586) as a food additive. 
4-HR (E 586) is an antioxidant authorised as a food additive in the EU to prevent melanosis in 
shrimps and related crustaceans that was previously evaluated for this specific use by the EU SCF in 
2003 and the JECFA in 1996. 
The SCF concluded that the available data did not allow the establishment of an ADI but the use was 
considered  as  toxicologically  acceptable  under  the  conditions  described  provided  residues  in 
crustacean meat did not exceed 2 mg/kg.  
JECFA,  based  on  the  available  data  in  animals,  was  unable  to  establish  a  numerical  ADI  but 
concluded that the treatment of crustaceans at concentrations of up to 50 mg 4-HR/L resulting in 
residue  levels  of  approximately  1 mg/kg  in  the  edible  portion  was  not  of  toxicological  concern. 
According to JECFA, “for more extensive use or higher levels of application, further toxicological 
data would be required, including a long-term toxicity study in mice that establishes a clear NOEL 
and the results of reproductive toxicity/teratogenicity studies”. 
Specifications for 4-HR have been defined in the Commission Regulation (EU) No 231/2012 and by 
JECFA (2006). The purity is specified to be not less than 98 %. 
Excretion of unlabelled 4-HR after oral application was measured in human subjects and male dogs. 
These studies provided an indication for absorption from the gastro-intestinal tract reaching a rate of 
20-30 % of the applied dose. Data on metabolites were sparse. There was an indication for excretion 
of conjugates of 4-HR via urine in the dog. The Panel noted the lack of ADME studies in the rat, the 
species  on  which  the  toxicological  studies  were  done.  The  Panel  considered  that  read-across  of 
resorcinol  ADME  data  to  4-HR  was  not  justified  because  of  differences  in  the  structure, 
physicochemical properties and biological behaviour of resorcinol and 4-HR. 
Studies of acute oral toxicity indicated LD50 of 750 mg 4-HR/kg bw in rats and 430 mg 4-HR/kg bw 
in guinea pigs.  
In the 13-week gavage study in mice mild to moderate nephropathy was found in males from a dose 
of 65 mg 4-HR/kg bw/day and above and in females from 125 mg 4-HR/kg bw/day and above. With 
regard to nephropathy no NOAEL could be identified and the Panel calculated the Benchmark dose 
(Appendix A). The BMDL10 values ranged from 7 to 21 mg 4-HR/kg bw/day for males and from 20 
to 90 mg 4-HR/kg bw/day for females. 
The 13-week gavage study in rats demonstrated a decreasing effect of 4-HR on body weight at a dose 
level from 125 mg/kg bw/day and above with the NOAEL of 62 mg/kg bw/day. At doses associated 
with  reduction  of  body  weight  adverse  effects  on  morphology  or  function  of  male  reproductive 
system were seen: reduction of the size of seminal vesicles (from 250 mg/kg bw/day), hypoplasia of 
seminal vesicles (from 500 mg/kg bw/day), and hypospermatogenesis at a high dose (1000 mg/kg 
bw/day) associated with mortality. 
Overall, the available  genotoxicity  data indicate that 4-HR is weakly genotoxic in some in vitro 
assays, with or without metabolic activation. In vivo UDS assay in rat liver did not show genotoxic 
effects. No adequate study on chromosomal damage in vivo was available.  
The Panel however noted the read-across from genotoxicity data on resorcinol was scientifically 
justified,  as  the  presence  of  an  aliphatic  chain  in  4-HR  was  not  expected  to  provide  additional Re-evaluation of 4-hexylresorcinol (E 586) as a food additive  
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genotoxic  potential  compared  to  resorcinol.  Based  on  the  available  experimental  data  on  4-HR, 
considering the lack of structural alerts for genotoxicity in the molecule, the genotoxic profile of 
resorcinol and the negative carcinogenicity studies in rodents with 4-HR, the Panel concluded that 4-
HR did not raise concern for genotoxicity. 
Carcinogenicity  studies  in  B6C3F1  mice  and  in  F344/N  rats  by  NTP  demonstrated  the  lack  of 
carcinogenic activity of 4-HR in doses amounting to 125 mg/kg bw/day. In treated mice of both sexes 
osteosclerosis was observed at increased incidences in the high dose group and  the incidence of 
nephropathy, a non-neoplastic lesion which was also reported in the 13-week-study, was increased in 
a dose dependent manner. With regard to nephropathy no NOAEL could be identified and the Panel 
calculated the Benchmark dose (Appendix A). In male mice the BMDL10 values ranged from 6 to 
8 mg 4-HR/kg bw/day and in female mice the BMDL10 value was 4 mg 4-HR/kg bw/day. 
Studies on reproductive and developmental toxicity of 4-HR are not available. 4-HR has been found 
to  be  a  spermicidal  agent  by  local  application  and  has  been  used  in  contraceptive  preparations, 
although  it  does  not  strip  human  spermatozoa  completely.  4-HR  was  reported  to  act  as  a 
transactivator  in  nanomolar  range,  without  direct  binding  to  estrogen  receptor  α  (ERα)  in  a 
competition assay in vitro. Whether the in vitro oestrogenic activity of 4-HR is associated with an 
adverse effect in an intact organism remains to be investigated. The Panel noted that the significance 
of these in vitro findings for risk assessment of 4-HR is difficult to ascertain in absence of additional 
studies  in  vivo  and  the  Panel  encourages  that  the oestrogenic  activity of 4-HR might be further 
explored.  
Human studies have pointed to the possibility of contact dermatitis in persons, who are allergic to 
resorcinol.  
When considering MPLs defined as residue of 2 mg/kg crustacean meat, mean exposure estimates 
from crustaceans‟ consumption range between 0.0 and 0.2 µg/kg bw/day for all population groups. 
High level exposures are estimated to be in the range of 0.0 – 1, 0.0 -2.5, 0.0 – 1.6, 0.5 – 3.3 and 0.1 – 
1.2 µg/kg bw/day, respectively for toddlers, children, adolescents, adults and the elderly. 
From the highest consumption level (95
th percentile of consumers only) of “crustaceans”, the highest 
exposure estimate of 3.3 µg/kg bw/day for adults calculated using MPLs defined as residue of 2 
mg/kg crustacean meat, results in MoS of 1200 when compared to the lowest BMDL10 of 4 mg/kg 
bw/day in carcinogenicity study in female mice. 
The Panel agreed with the SCF that the database did not allow the establishment of an ADI. In doing 
so the Panel admitted the limitation of the biological and toxicological database, which included the 
lack  of  ADME  studies  in  the  rat,  the  species  in  which  the  available  toxicological  studies  were 
performed, and of  the reproductive and developmental toxicity studies as well as the inability to 
read-across for these endpoints from resorcinol to 4-HR due to differences between the compounds in 
the structure, physiochemical properties and biological behaviour.  
However, considering that  
  4-HR is only permitted as a food additive for a specified use in crustaceans,  
  the  BMDL10  values  identified  by  the  Panel  were  based  on  the  most  sensitive  endpoint 
(nephropathy) and  
  the MoS between the lowest BMDL10 in female mice from the carcinogenicity study was 
1200 and Re-evaluation of 4-hexylresorcinol (E 586) as a food additive  
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  the highest exposure estimate based on MPL defined as residue of 2 mg 4-HR/kg was 3.3 
µg/kg bw/day  
the Panel concluded that, at the currently permitted use and use levels (as residue), 4-HR as food 
additive is not of safety concern. 
The Panel considered that any increase in the permitted use levels and/or extension of the uses to 
other food categories would require additional investigations in vivo such as extended one-generation 
reproductive toxicity study (OECD TG No. 443). 
The Panel concluded that the present database does not justify revision of the SCF‟s evaluation. The 
Panel agreed with the SCF that the database does not allow the establishment of an ADI.  
The Panel concluded that the MoS value calculated by the Panel was sufficient given the conservative 
nature  of  exposure  estimates  and  limited  uses.  Accordingly  the  Panel  concluded  that  4-HR  was 
toxicologically acceptable for prevention of melanosis in shrimps and related crustaceans provided 
residues in crustacean meat do not exceed 2 mg/kg.  
The  Panel  noted  that  the  information  on  actual  residual  levels  in  crustaceans  was  limited  and 
recommends monitoring of these levels in the European market. Re-evaluation of 4-hexylresorcinol (E 586) as a food additive  
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BACKGROUND AS PROVIDED BY THE COMMISSION 
Regulation (EC) No 1333/2008
4 of the European Parliament and of the Council on food additives 
requires that food additives are subject to a safety evaluation by the European Food Safety Authority 
(EFSA) before they are permitted for use in the European Union. In addition, it is foreseen that food 
additives must be kept under continuous observation and must be re-evaluated by EFSA.  
For this purpose, a programme for the re -evaluation of food additives that were already permitted in 
the European Union before 20 January 2009 has been set up under Regulation (EU) No 257/2010
5. 
This Regulation also foresees that food additives are re -evaluated whenever necessary in light of 
changing conditions of use and new scientific information. For efficiency and practical purposes, the 
re-evaluation should, as far as possible, be conducted by group of food additives according to the 
main functional class to which they belong. 
The order of priorities for the re-evaluation of the currently approved food additives should be set on 
the basis of the following criteria: the time since the last evaluation of a food additive by the 
Scientific Committee on  Food (SCF) or by EFSA, the availability of new scientific evidence, the 
extent of use of a food additive in food and the human exposure to the food additive taking also into 
account the outcome of the Report from the Commission on Dietary Food Additive Int ake in the EU
6 
of 2001. The report “Food additives in Europe 2000
7” submitted by the Nordic Council of Ministers 
to  the  Commission,  provides  additional  information  for  the  prioritisation  of  additives  for  re-
evaluation. As colours were among the first additives to be evaluated, these food additives should be 
re-evaluated with the highest priority. 
In 2003, the Commission already requested EFSA to start a systematic re-evaluation of authorised 
food additives. However, as a result of the adoption of Regulation (EU) 257/2010 the 2003 Terms of 
Reference are replaced by those below. 
TERMS OF REFERENCE AS PROVIDED BY THE COMMISSION 
The Commission asks the European Food Safety Authority to re-evaluate the safety of food additives 
already permitted in the Union before 2009 and to issue scientific opinions on these additives, taking 
especially into account the priorities, procedure and deadlines that are enshrined in the Regulation 
(EU) No 257/2010 of 25 March 2010 setting up a programme for the re-evaluation of approved food 
additives in accordance with the Regulation (EC) No 1333/2008 of the European Parliament and of 
the Council on food additives. 
                                                       
4  OJ L 354, 31.12.2008, p. 16.  
5  OJ L 80, 26.03.2010, p19 
6  COM(2001) 542 final. 
7  Food Additives in Europe 2000, Status of safety assessments of food additives presently permitted in the EU, Nord ic 
Council of Ministers. TemaNord 2002:560. Re-evaluation of 4-hexylresorcinol (E 586) as a food additive  
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ASSESSMENT 
1.  INTRODUCTION 
The present opinion deals with the re-evaluation of the safety of 4-hexylresorcinol (4-HR) (E 586) 
when used as a food additive. 
4-HR (E 586) is an antioxidant authorised as a food additive in the EU to prevent the development of 
melanosis in shrimps and related crustaceans. The compound was previously evaluated by the EU 
Scientific Committee for Food (SCF) in 2003 and the Joint FAO/WHO Expert Committee on Food 
Additives (JECFA) for this specific use only (JECFA, 1996). 
The Panel was not provided with a newly submitted dossier and no new toxicological or biological 
information was submitted for the present re-evaluation neither following a public call for data
8. The 
Panel based its evaluation on previous evaluations  and additional literature that became available 
since then. Not all original studies on  which previous evaluations were based were available for the 
present re-evaluation. 
2.  TECHNICAL DATA 
2.1.  Identity of the substance 
4-HR (E 586) is an antioxidant with the molecular formula C12H18O2. It has a molecular weight of 
194.27g/mol. The CAS Registry Number is 136-77-6 and the EINECS number is 205-257-4. The 
structure contains a dihydroxybenzene with a hexyl group in the 4 position, the hydroxyl groups are 
on positions 1 and 3 of the aromatic ring (Frankos et al., 1991). The structural formula of 4-HR is 
presented in Figure 1. 
OH O H
C H3
 
Figure 1:   Structural formula of 4-HR 
 
4-HR  is  freely  soluble  in  ether,  and  acetone  and  very  slightly  soluble  in  water  (JECFA,  2006; 
Commission  Regulation  (EU)  No  231/2012).  According  to  EC  and  JECFA  specifications  the 
substance is white powder with a melting point range between 62 and 67 °C and a pKa value of 10.03. 
The boiling point is 333 – 335 °C and the LogPo/w is 3.88 (The Merck Index, 2006; Lide, 2009).  
The substance has several synonyms; the most common are: 1,3-dihydroxy-4-hexylbenzene, 4-hexyl-
1,3-benzenediol, 4-hexyl-1,3-dihydroxybenzene and 4-hexylresorcine. 
 
                                                       
8  EFSA‟s call for data on miscellaneous food additives permitted in the EU and belonging to several functional classes, June 
2010.  http://www.efsa.europa.eu/en/dataclosed/call/ans100609.pdf Re-evaluation of 4-hexylresorcinol (E 586) as a food additive  
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2.2.  Specifications 
Specifications of the substance have been defined in Commission Regulation (EU) No 231/2012
9 and 
by JECFA in 1998 (JECFA, 2006) (Table 1). 
Table 1:    Specifications for 4-HR (E 586) according to Commission Regulation (EU) No 231/2012 
and by JECFA (JECFA, 2006) 
 
Commission Regulation (EU)  
No 231/2012  JECFA (2006) 
Assay 
Not less than 98 % on the dried 
basis 
Not less than 98.0 % on the dried 
basis 
Purity     
Acidity  Not more than 0.05 %  Not more than 0.05 % 
Sulphated ash  Not more than 0.1 %  Not more than 0.1 % 
Resorcinol and other phenols 
Shake about 1 g of the sample with 
50 mL of water for a few minutes, 
filter, and to the filtrate add 3 drops 
of ferric chloride TS. No red or 
blue colour is produced 
Shake about 1 g of the sample with 
50 mL of water for a few minutes, 
filter, and to the filtrate add 3 drops 
of ferric chloride TS. No red or 
blue colour is produced 
Nickel  Not more than 2  mg/kg  Not more than 2 mg/kg 
Lead  Not more than 2 mg/kg   Not more than 2 mg/kg  
Mercury  Not more than 3 mg/kg   Not more than 3 mg/kg  
2.3.  Manufacturing process 
No information is available on the manufacturing process for the 4-HR used specifically as a food 
additive. 
4-HR  can  be  manufactured  in  the  following  4  steps:  1)  resorcinol  and  caproic  acid  react  under 
elevated pressure and temperature in the presence of a catalyst, resulting in conversion of the two 
reactants  to  4-caproylresorcinol;  2)  purification  of  the  mixture  by  extraction  and  distillation;  3) 
catalytic hydrogenation of the purified 4-caproylresorcinol to yield crude 4-HR,4) purification and 
isolation of 4-HR by filtration, distillation, crystallization and drying.  The catalysts used are zinc 
amalgam and nickel (JECFA, 1996). 
2.4.  Methods of analysis in food 
A high-performance liquid chromatography (HPLC) method for analysis of 4-HR in shrimps has been 
developed by Jonker & Dekker (2000). Methanolic extracts were separated using a reversed-phase 
column and fluorimetric detection (excitation: 280 nm and emission: 310 nm). The recovery was 
about 80 % at 1.5 – 2.5 mg/kg. The relative standard deviation was 2.1 %. Limits of quantification 
and detection were 6.59 and 1.98 ng/mL extract, respectively, corresponding to 0.26 and 0.08 mg/kg 
in shrimp. 
Other  HPLC  analytical  procedures  for  quantification  of  residual  4-HR  on  treated  shrimp  were 
described in the literature (Frankos et al., 1991; Iyengar et al., 1991). 
                                                       
9  Commission  Regulation  (EU)  No  231/2012  of  9  March  2012  laying  down  specifications for  food  additives listed  in 
Annexes II and III to Regulation (EC) No 1333/2008 of the European Parliament and of the Council. OJ L 83, 22.3.2012, p 
1-295. Re-evaluation of 4-hexylresorcinol (E 586) as a food additive  
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2.5.  Reaction and fate in food 
Guandalini et al., 1998, monitored 4-HR residues in shrimps. Shrimps, after being caught, were kept 
on ice in a cold store of the fishing boat for 2-3 hours, until it arrived at the port. The incubation 
experiment was carried out on land in duplicate and went on for 11 days. Shrimps (1500 mg batches 
each) were treated by dipping for 1 minute in sea water resulting in concentrations of 4-HR of 25 mg, 
50 mg and 100 mg/kg shrimp. As control one group was treated with Na2S2O5 (1000 mg/kg shrimp). 
After treatment the shrimps were placed in boxes, covered with a nylon film with some ice on it, and 
stored at 0 ± 1°C. The ice was replaced daily. During the first 5 days, residues in the shrimp were 
analysed using the HPLC method described by King et al. (1991). All analyses were run in duplicate. 
The  shrimps  were  peeled,  heads  were  removed,  and  only  the  muscular tissue was  analysed (3 g 
samples).  
At all three concentrations tested, a decrease in the residual 4-HR in the shrimp tissue was observed. 
At dipping concentration of 25 mg 4-HR/kg shrimp the level of 4-HR decreased from 20 mg/kg tissue 
after 3 hours to 0.9 mg/kg tissue after 5 days. At dipping concentration of 50 mg 4-HR/kg shrimp the 
level 4-HR decreased from 42 mg/kg tissue after 3 hours to 1.8 mg/kg tissue after 5 days. At dipping 
concentration of 100 mg 4-HR/kg shrimp, 85 mg/kg tissue was observed after 3 hours and 1.9 mg/kg 
tissue after 5 days. From the fifth day until the 11
th day the residues of 4-HR decreased slowly; within 
this period the level remained virtually unchanged in the 25 mg/kg shrimp group: 0.9-0.8 mg/kg. On 
the 11
th day residues averaged 0.8 mg 4-HR/kg in the 50 mg 4-HR/kg group and 1.1 mg 4-HR/kg in 
the 100 mg 4-HR/kg group. 
2.6.  Case of need and proposed uses 
Maximum Permitted Levels (MPLs) of 4-HR (E 586) as residue have been defined in the Annex II of 
Regulation (EC) No 1333/2008
10 on food additives for use in foodstuffs. 
Currently, 4-HR (E 586) is an antioxidant authorized as food additive in the EU with one MPL of 2 
mg/kg  as residue in  fresh, frozen or deep -frozen crustacean meat of unprocessed molluscs and 
crustaceans. 
4-HR is used as  an antioxidant to prevent the development of melanosis (brown or black spot) in 
shrimps  and  related  crustacean s.  The  mechanism  of  browning  prevention  is  via  inhibition  of 
polyphenol oxidase (PPO) (for details see Arias et al., 2007).  
Table 2 summarises foods that are permitted to contain 4-HR (E 586) and the corresponding MPLs as 
set by Annex II of Regulation (EC) No 1333/2008. 
                                                       
10   Commission Regulation (EU) No 1129/2011 of 11 November 2011 amending Annex II to Regulation (EC) No 1333/2008  
   of the European Parliament and of the Council establishing a Union list of food additives.  Re-evaluation of 4-hexylresorcinol (E 586) as a food additive  
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Table 2:   MPL  of  4-HR  (E 586)  in  foods  according  to  the  Annex  II  of  Regulation  (EC) 
No 1333/2008 
Category 
number  Foods  Restrictions/exception 
Maximum level 
(mg/L or mg/kg 
as appropriate) 
9.1.2  Unprocessed molluscs and crustaceans 
only in fresh, frozen or deep-
frozen crustacean meat  2* 
*  as a residue 
 
2.6.1.  Actual and reported level of use of 4-HR  
Most food additives in the EU are authorised at a specific MPL. However, a food additive may be 
used at a lower level than the MPL. No data on the actual residual level of 4-HR in crustacean meat 
for fresh, frozen and deep-frozen crustaceans were made available to the Panel for the present re-
evaluation.  
According to JECFA (JECFA, 1996), crustaceans are treated at concentrations of up to 50 mg 4-HR/L 
of  aqueous  dipping  solution,  resulting  in  residue  levels  in  the  edible  portion  of  crustacean  of 
approximately  1 mg  4-HR/kg  shrimp.  However,  there  exist  uncertainties  on  the  residual  levels 
reported in the literature. 
Slattery et al. (2009) described a recommended practice for dipping shrimps for 2 minutes into a 
solution  containing  50 mg  4-HR/L.  They  compared  this  recommended  treatment  with  modified 
treatments after extending dipping times, lowering concentrations of 4-HR in the solution as well as 
using different batch sizes of shrimp dipped into the solution. All treatments resulted in residue levels 
of below 1 mg 4-HR/kg in shrimps after 4 days except dipping shrimps for 72 hours into a solution 
with 20 mg/L (1.14 mg/kg shrimp). Residue levels decreased during the 4 days of storage on ice. 
Smaller sizes of batches resulted in better prevention of melanosis because of higher residue levels of 
4-HR.  Higher  concentrations  and  longer  dipping  times  did  also  increase  the  residue  levels  and 
resulted in a lower percentage of shrimps with black spots. 
Previous evaluations reported that dipping shrimps for only 1 min into a solution containing 50 mg 4-
HR/L inhibits the formation of shrimp black spot and is assumed to be the lowest level of 4-HR to 
effectively prevent melanosis for a storage period of 12 days (Otwell et al. 1992, Frankos et al., 1991). 
Other  studies  observed  that  treating shrimp  for a 1 min dip at concentrations of  50 mg 4-HR/kg 
shrimp could effectively prevent the oxidative process until day 5; after day 6 the shrimps become 
nearly unacceptable (Guandalini et al. 1998). According to Montero et al. (2006), after a 1 hour dip 
already at day four a melanosis was perceptible at the shrimps. This is in line with another study using 
a solution of 100 mg 4-HR/L to dip shrimps for 1 hour where after 4 days about 30 % of the shrimps 
was not acceptable and reaching 100 % after 7 days of storage (Martinez-Alvarez et al. 2008). The 
objective of most studies is to compare the treatment of shrimps with 4-HR with other substances that 
might be able to prevent melanosis. From those studies it becomes clear that residual levels of 4-HR 
also depend on shrimp species and the season in which shrimps are caught (Montero et al. 2004). 
Residue levels were not reduced in a study applying different combination of freezing, cooking and 
washing after dipping shrimps into 4-HR (Mendes et al. 2006). The same authors concluded that there 
were additional studies needed especially to investigate the influence of ice storage before and after 
dipping on the residue levels of 4-HR. Slattery et al. (2009) mention that residue levels of 4-HR were 
affected by strong light. Further it seemed that prawns, dipped live, had higher residues than prawns 
killed before dipping (Slattery et al. 1995). Also different shrimp species seemed to react differently 
to the treatment with 4-HR (Montero at al. 2006).  Re-evaluation of 4-hexylresorcinol (E 586) as a food additive  
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Table 3 provides analytical data on the use levels of 4-HR in foods as reported in literature. In this 
table the most common dipping time (i.e. 1 min) and 4-HR concentration (i.e. 50 mg 4-HR/kg shrimp) 
was  used  for  comparison.  If  residue  levels  were  available  for  more  than  one  reference  date  the 
residues on the sixth day were used in accordance with the findings of Guandalini et al. (1998) who 
observed that for the group at concentration of 50 mg 4-HR/kg shrimp,  could effectively prevent the 
oxidative process  until day 5 (see above).  
In accordance with Slattery et al. (2009), Table 2 shows that all residues are below the maximum 
levels of 2 mg/kg shrimp. Besides uncertainties on the 4-HR residues in shrimps it is not clear from 
other literature whether the levels of 4-HR will decrease over time as normally expected. Scenarios 
also exist showing an increase in 4-HR residues over storage time (Montero et al. 2006). A possible 
explanation given by the authors is that for longer dipping times (1 hour), the release of 4-HR from 
the muscle will be reduced. Also the results of field trials do not show a clear increase of mean values 
over time and therefore seem not very robust. Montero et al. (2006) speculated that there might be an 
interaction at longer dipping times between 4-HR and muscle components that interferes with the 
release of 4-HR from the muscle. But this presumption is not in line with the results of Slattery et al. 
(2009) showing a decrease also for longer dipping times. 
Most of the data reported in literature refer to experimental studies and do not refer to market control 
data. Because of this and of the different results as well as remaining uncertainties on how 4-HR is 
exactly  used  and  on  how  residue  levels  are  influenced  by  different  factors  it  is  not  possible  to 
establish a reported use level. Montero et al. (2006) even doubt that due to the influence of different 
processing technologies it is possible to reduce 4-HR levels to acceptable values below the maximum 
limit. 
Therefore the Panel decided to estimate exposure based on a residue level of 1.2 mg 4-HR/kg shrimp 
reported by Guandalini et al. (1998) at day 6 after treatment and a dipping time of 1 min in a solution 
of 50 mg 4-HR/kg shrimp and assumed that this treatment is most representative for the actual use. 
But it should be kept in mind that it is uncertain whether these levels are representative for real 
market situations, as there are no monitoring data available. 
In  addition  the  application  of  4-HR  in  shrimps  by  spraying  or  dusting  instead  of  dipping  was 
described (Montero et al. 2006, Montero et al. 2004). However, since it is totally unclear whether 
such treatments were applied they will not be considered here.  
In addition to the permitted use in crustaceans also the use of 4-HR to preserve apple slices (Luo et al. 
1996), apple juice (Iyidogan et al. 2004) or mango puree (Guerrero-Beltran et al. 2005) was reported 
in literature. The exposure from these uses is not considered in the exposure assessment since there is 
no authorisation for those uses. Re-evaluation of 4-hexylresorcinol (E 586) as a food additive  
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Table 3:   Summary of the 4-HR levels (mg/kg shrimp) in crustaceans used in the refined exposure 
assessment 
Category 
number 
Food 
items  MPL* 
Analytical data 
Opta Food 
Ingredients, 
INC 
Field trials 
(white 
shrimp) 
Opta Food 
Ingredients, 
INC 
Laboratory 
analysis 
(pink 
shrimp) 
Iyengar 
et al. 
1991 
(pink 
shrimp) 
Iyengar et 
al. 1991 
(white 
shrimp) 
Guandalini 
et al. 1998 
(pink 
shrimp) 
9.1.2 - 
Unprocessed 
crustaceans 
and molluscs 
Head-on 
crustaceans  2  0.4  0.5  0.6  0.5  - 
Head-less 
crustaceans   2  1.2  1.1  1.0  1.0  1.2 
comments 
calculated 
as mean of 
reported 
residues of 
day 6 
calculated as 
mean of 
reported 
residues of 
day 6 
mean of 
day 0. 1. 
6 and 12 
mean of 
day 2. 6 
and 12 
residue 6 
days after 
treatment 
decreasing 
to 
0.8 mg/kg 
shrimp at 
day 11 
*  as a residue 
 
2.7.  Information on existing authorisations and evaluations 
The  SCF  evaluated  4-HR  (SCF,  2003),  and  concluded  that  the  available  data  did  not  allow  the 
establishment of an ADI. The use was considered as toxicologically acceptable under the conditions 
described provided residues in crustacean meat did not exceed 2 mg/kg.  
4-HR was evaluated by JECFA in 1996 (JECFA, 1996). Based on the available data in animals, the 
Committee was unable to establish a numerical ADI but concluded that the treatment of crustaceans at 
concentrations of up to 50 mg/L, resulting in residue levels of approximately 1 mg/kg in the edible 
portion, was not of toxicological concern. According to JECFA, “for more extensive use or higher 
levels of application, further toxicological data would be required, including a long-term toxicity 
study in mice that establishes a clear NOEL and the results of reproductive toxicity/teratogenicity 
studies”. 
A safety evaluation of 4-HR was conducted to affirm the generally recognised as safe (GRAS) status 
of the substance for use as a processing aid for prevention of melanosis in shrimp. (Frankos et al., 
1991). Frankos et al. (1991) proposed an ADI for 4-HR of 0.11 mg/kg bw/day by applying a safety 
factor of 100 to the estimated NOEL of 10.7 mg/kg/day (based on incidence of nephropathy induced 
in female mice at the lowest dose tested of 62.5 mg/kg/day with 82 % compared to the control with 
14 %) from a 2-year-study in mice conducted by the National Toxicology Program (NTP, 1988). 
2.8.  Exposure 
According to JECFA (1996), 4-HR is applied as an aqueous solution at concentrations of 50 mg/L, 
resulting in residue levels in the edible portion of crustacean of approximately 1 mg/kg. The estimated 
intake of the compound resulting from this use was 1-8 μg/person/day.  Re-evaluation of 4-hexylresorcinol (E 586) as a food additive  
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Frankos  et  al.  (1991)  considered  that  the residual data developed for fresh shrimps (heads-on or 
headless) are most representative for use conditions and potential consumption of 4-HR. Accordingly 
Frankos et al. (1991) considered in the exposure calculation that average 4-HR residues measured in 
fresh heads-on shrimp were 0.4 ± 0.09 mg/kg (mean ± standard deviation) after l-min dipping time 
and 0.7 ± 0.13 mg/kg after 15-min dipping time. The average residual 4-HR concentrations measured 
in fresh headless shrimp were 0.9 ± 0.27 mg/kg for l-min dipping time and 2 ± 0.41 mg/kg for 15-min 
dipping time (Frankos et al., 1991). Based on consumption data from Market Research Corporation of 
America Information Service menu census data (MRCA), a total intake of 0.024 (average) and 0.065 
µg/kg/day (90
th percentile) was calculated (Frankos et al., 1991). 
Food consumption data used for exposure assessment 
Since  2010,  the  EFSA  Comprehensive  European  Food  Consumption  Database  (Comprehensive 
Database) has been populated with data from national information on food consumption at a detailed 
level. Competent authorities in the European countries provide EFSA with data on the level of food 
consumption by the individual consumer from the most recent national dietary survey in their country 
(cf. Guidance of EFSA „Use of the EFSA Comprehensive European Food Consumption Database in 
Exposure Assessment‟ (EFSA, 2011b). 
Overall, the food consumption data gathered at EFSA were collected by different methodologies and 
thus direct country-to-country comparison should be made with caution. 
Summary  statistics  from  the  Comprehensive  Database  can  be  used  as  a  screening  tool  to  assess 
chronic  exposure  to  food  additives.  Intake  statistics  have  been  calculated  based  on  individual 
consumption over the total survey period excluding surveys with only one day per subject. Surveys 
with less than 60 subjects were considered as non-reliable to estimate exposure.  
Mean consumption is calculated on the whole population whereas the high levels are calculated on the 
consumers only. When the number of consumer per population groups and food category was above 
60, the high level calculated is the 95
th percentile. When the number of consumer per population 
groups and food category was below 60, then the high level is estimated as the mean consumption of 
consumers only. This is due to the minimum number of observations necessary to estimate the 95
th 
percentile. 
The  Panel  estimated  chronic  exposure  for  the  following  population  groups:  toddlers,  children, 
adolescents, adults and the elderly. Calculations were performed using individual body weights. 
Thus, for the present assessment, food consumption data were available from 26 different dietary 
surveys carried out in 17 different European countries as mentioned in the Table 4:  Re-evaluation of 4-hexylresorcinol (E 586) as a food additive  
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Table 4:   Population groups considered for the exposure estimates of 4-HR 
Population  Age range  Countries with food consumption surveys covering 
more than one day 
Toddlers  From 12 up to and including 35 
months of age  Bulgaria, Finland, Germany, The Netherlands 
Children
11  From 36 months up to and 
including 9 years of age 
Belgium, Bulgaria, Czech Republic, Denmark, Finland, 
France, Germany, Greece, Italy, Latvia, The Netherlands, 
Spain, Sweden  
Adolescents  From 10 up to and including 17 
years of age 
Belgium, Cyprus, Czech Republic, Denmark, France, 
Germany, Italy, Latvia, Spain, Sweden 
Adults  From 18 up to and including 64 
years of age 
Belgium, Czech Republic, Denmark, Finland, France, 
Germany, Hungary, Ireland, Italy, Latvia, The Netherlands, 
Spain, Sweden, UK  
The 
elderly
11 
From 65 years and older  Belgium, Denmark, Finland, France, Germany, Hungary, 
Italy 
 
Consumption records were codified according to the FoodEx classification system (EFSA, 2011a). 
Nomenclature from FoodEx classification system has been linked to the Food Classification System 
as presented in the Annex II of Regulation (EC) N° 1133/2008, part D, to perform exposure estimates.  
Food group 9.1.2 – „Unprocessed crustaceans and molluscs‟, as in the nomenclature legislation and 
also available in the Food Additive Intake Model (FAIM), is the decisive group for this evaluation. 
However, since this food group contains also molluscs for which 4-HR is not authorised, a calculation 
was  performed  using  consumption  of  crustaceans  only  from  Comprehensive  (FoodEx  level  2 
category).  
2.8.1.  Exposure to 4-HR from its use as food additive 
Exposure to 4-HR from its use as food additive has been calculated by using the MPL defined as 
residue of 2 mg/kg in the Annex II of Regulation (EC) No 1333/2008
12 on food additives for use in 
foodstuffs combined with national consumption data for the five population groups (Table  4) as well 
as  using  reported  use  level  of  1.2  mg/kg.  Average  exposure  was   calculated  using  the  mean 
consumption amount of total population and high level exposure was calculated by using the 95
th 
percentile of consumers only.  
The Panel noted that this approach could results in conservative estimates of exposure as it was 
assumed that the food category considered contain 4-HR at the MPL. 
Table  5  summarises  the  estimated  exposure  to  4-HR  from  its  use  as  food  additive  of  all  five 
population groups. 
                                                       
11   The terms “children” and “the elderly” correspond respectively to “other children” and the merge of “elderly” and “very 
elderly” in the Guidance of EFSA on the „Use of the EFSA Comprehensive European Food Consumption Database in 
Exposure Assessment‟ (EFSA, 2011b). 
12   Commission Regulation (EU) No 1129/2011 of 11 November 2011 amending Annex II to Regulation (EC) No 1333/2008 
  of the European Parliament and of the Council establishing a Union list of food additives.  Re-evaluation of 4-hexylresorcinol (E 586) as a food additive  
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Table 5:   Summary of anticipated exposure to 4-HR from its use as food additive using MPL 
and use levels from the literature as residue in five population groups 
    Toddlers 
 
 Children  Adolescents 
 
Adults 
 
Elderly 
Food group 
  (12-35 
months)  (3-9 years) (10-17 years)  (18-64 
years)  (≥65 years) 
    µg/kg 
bw/day 
µg/kg 
bw/day 
µg/kg 
bw/day 
µg/kg 
bw/day 
µg/kg 
bw/day 
  Estimated exposure using MPL  
9.1.2. - only in 
fresh, frozen or 
deep-frozen 
crustacean meat 
Crustaceans 
  Mean exposure 
<0.05 - 
<0.05 
<0.05 - 
0.2  <0.05 - 0.2 
<0.05 - 
0.2 
<0.05 - 
0.1 
  Exposure 95
th 
percentile 
<0.05 - 
1.0 
<0.05 - 
2.5  <0.05 - 1.6  0.5 - 3.3  0.1 - 1.2 
  Estimated exposure using use level from the literature 
9.1.2. - only in 
fresh, frozen or 
deep-frozen 
crustacean meat 
Crustaceans 
  Mean exposure 
<0.05 - 
<0.05 
<0.05 - 
0.1  <0.05 - 0.1 
<0.05 - 
0.1 
<0.05 - 
<0.05 
  Exposure 95
th 
percentile 
<0.05 - 
0.6 
<0.05 - 
1.5  <0.05 - 1.0  0.3 - 2.0  0.1 - 0.7 
A high fish consumer group within the French population was examined within the Calipso survey 
(Leblanc  et  al.,  2006).  This  survey  is  not  included  in  the  EFSA  database  because  it  is  not  
representative  at  national  level,  but  can  give  an  indication  on  the  conservatism  of  exposure 
assessments based on consumption data from the Comprehensive  Database. From this survey the 
mean consumption of crustaceans was about 11.7 - 12.6 g/day for the different sub-populations (men 
18-64 years, women 18-64 years, elderly 65+ years and women of child-bearing age (18-44 years). 
Using the default body weight of 70 kg recommended for European population by EFSA ( EFSA 
Scientific Committee, 2012) the mean exposure for this specific group of high French fish consumers 
is between 0.333 and 0.361 µg/kg bw/day. This is about twice of the mean exposure of crustaceans 
calculated using the national surveys. 
2.8.2.  Exposure via other sources 
4-HR has a long history of human pharmaceutical use (SCF, 2003). It is used as a phenolic antiseptic 
in  mouth-washes,  in  the  form  of  lozenges  for  the  treatment  of  sore  throat  and  topically  for  the 
treatment of minor infections of the skin and mucous membranes, e.g. in skin wound cleansers. It is 
also used in vaginal spermicidal preparations. Formerly it was used as an anthelmintic (Martindale, 
2011; NCI, 2011; Consumer Healthcare Products Association, 2010; Ph.Eur. Comm., 2005). It is 
listed as an active ingredient with the UNII Code R9QTB5E82N for “over-the-counter” products 
(FDA, 2010). The substance is listed under ATC code R02AA12 as throat preparations, antiseptics in 
the anatomical therapeutic chemical classification of the WHO (2011). Throat lozenges containing 2.4 
- 4 mg of 4-HR for use as an oral antiseptic are available over the counter in some countries (Gilman 
et al., 1985). Assuming a dose of 2.5 mg/lozenge and a maximum of 10 lozenges per day will result in 
a worst case estimate of intake of about 350 µg/kg bw/day assuming a 70 kg body weight. The 
application  of  throat  lozenges  containing  4-HR  is  not  assumed  to  be  relevant  for  chronic  intake 
because of short-term therapeutic use. 
Additionally, highly pure 4-HR (>99 % purity) can also be used as skin lightener (topical application; 
Chaudhuri, 2010). 4-HR is used as an anthelmintic in veterinary medicine (Merck-Index 2006), but 
because  no  maximum  residue  levels  (MRLs)  have  been  set  for  food  producing  animals  it  is not 
possible to undertake an exposure assessment. Re-evaluation of 4-hexylresorcinol (E 586) as a food additive  
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3.  BIOLOGICAL AND TOXICOLOGICAL DATA 
The evaluation of the core endpoints in this document was performed with the data available for the 
JECFA evaluation in 1996 and for the SCF‟s evaluation in 2003. Literature search in the databases 
Toxline, Medline, and SciFinder (including Chemical Abstracts) revealed only few studies. 
3.1.  Absorption, distribution, metabolism and excretion 
3.1.1.  Animal studies 
Male  dogs  (body  weight  15-25  kg)  were  given  single  doses  of  1g  (n=6)  or  3  g  (n=4)    of 
hexylresorcinol,  assumed  by  the  Panel  and  JECFA  to  be  4-HR  as  crystals  in  gelatine  capsules 
(Robbins,  1931).  Excretion  was  monitored  in  urine  and  faeces  using  a  colorimetric  method 
(quantification threshold: “1 part in 10:25,000”). Urine samples were collected via catheterisation 
every hour for six to eight hours and then in 2-hour intervals for the next four to six hours, and after 
24 hours. Faeces were collected and analysed until it was not possible to detect hexylresorcinol or 
until most of the 4-HR was recovered. After administration of 1 g, an average of 29 % of the dose was 
detected  in  urine  and  67 %  in  faeces;  the  total  recovery  was  96 %.  After  application  of 1 g the 
compound excretion in the urine began during the first hour, reached the maximum rate of excretion 
during the 3
rd to 4
th hour after which the rate gradually declined until at the 12
th hour the 4-HR was 
reported practically not detected by the colorimetric method. Only traces of 4-HR were detected in 
urine collected 24 hours after application. When the dose was 3 g, an average of 17 % of 4-HR was 
excreted in urine and 73 % in faeces (total recovery 90 %). The maximum rate was reached during the 
5
th hour and after the 6
th hour the rate fell again, until at the 24
th to 36
th hour the urine was free of 
hexylresorcinol. In additional experiments when 4-HR was given in olive oil or followed by paraffin 
oil, the excretion of 4-HR in the urine was reduced (Robbins, 1931). The Panel noted that this study 
provided only an indication for absorption from the gastrointestinal tract because of methodological 
limitations; the absorption rate might reach 20-30 % of the applied dose. This study was performed 
with unlabelled 4-HR, the colorimetric method for the estimation of phenolic compounds in the urine 
and  faeces  provided  a  rough  quantification  without  differentiation  between  unchanged  4-HR  and 
metabolites, data on amounts detected in faeces did not distinguish between unabsorbed compound 
and  absorption  followed  by  excretion  via  bile,  excretion  via  exhalation  of  metabolites  was  not 
considered and distribution and retention in the body was not accounted for. 
The tissue distribution of 4-HR was studied in dogs given single doses of 1g as crystals in gelatine 
capsules (Robins, 1931) (no further details presented). The concentrations were not high enough to be 
detected by the test method used. Regarding the state of 4-HR in the urine the author reported that 4-
HR excreted in the urine was mainly in a conjugated state (about 95 %) and in the faeces in “a free 
state”. The Panel noted that no methodological details were presented for this statement.  
3.1.2.  Human studies 
Two men (no further details) ingested a dose of 1 g unlabelled hexylresorcinol, assumed by the Panel 
and JECFA to be 4-HR, and the excretion via faeces and urine was analysed using a colorimetric 
method  for  the  estimation  of  phenolic  compounds  in  these  excreta  (no  data  about  exhalation  of 
metabolites)  (Robbins,  1935).  The  applied  method  provided  a  rough  quantification  without 
differentiation between unchanged 4-HR and metabolites (e.g. conjugates). In control trials, phenolic 
compounds in excreta were also measured. In the first subject, 135 mg of the applied substance was 
excreted via urine within 12 hours. In the second subject, 232 mg of the applied substance was found 
in urine within 12 hours. In both subjects, no phenolic compounds were detected in urine sampled 
later than 12 hours after ingestion. In the first subject, 633 mg of the applied amount was found in 
faeces “passed after dosing” (no further details) and in the second subject 690 mg. The total recovery 
was 77 % in the first subject and 92 % in the second subject. An average of 18 % of the dose was Re-evaluation of 4-hexylresorcinol (E 586) as a food additive  
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recovered in urine, and faecal excretion accounted for 64 % of the dose (Robbins, 1935). The Panel 
noted that the study did not provide sufficient data for estimation of an absorption rate since data on 
amounts  detected  in  faeces  did  not  distinguish  between  unabsorbed  compound  and  absorption 
followed by excretion via the bile, excretion via exhalation of metabolites was not considered, and 
distribution and retention in the body was not accounted for. 
It was reported that 4-HR was excreted via the urine mainly in the form of an ethereal  sulphate 
conjugate  (Goodman  &  Gilman,  1970;  cited  in  JECFA,  1996),  but  the  original  report  was  not 
available to the Panel. 
Overall, the Panel noted that studies with unlabelled 4-HR, in which excretion via faeces and urine 
after oral application was measured were performed in male dogs and human subjects. The validity of 
these  old  studies  was  limited  due  to  methodological  insufficiencies.  The  studies  provided  an 
indication for absorption from the gastro-intestinal tract. The data on metabolic pathways were not 
available. No data on ADME of 4-HR were available in the rat, the species on which toxicological 
studies were performed. 
The  Panel  considered  whether  data  on  ADME  of  resorcinol  could  be  read  across  to  4-HR.  In 
particular the Panel noted that resorcinol was a simple dihydroxyphenol whereas 4-HR contained an 
aliphatic 6-carbon-chain attached to the dihydroxyphenol moiety. Whilst resorcinol was soluble in 
water, a log Pow of 0.80 and had a pKa of 9.32, 4-HR was insoluble in water, a log Pow of 3.88 and had 
a  higher  pKa  of  10.03.  These  solubility  differences  in  water  and  octanol  are  likely  to  alter  the 
absorption, metabolism and distribution of the compounds. This is supported by the limited biological 
data available. Resorcinol (about 100 mg/kg bw orally) was rapidly and extensively absorbed (80-
100 %) and mainly excreted in urine of rats (91-93 % according to Kim and Matthews 1987) and 
rabbits (77 % according to Garton and Williams 1949) whereas for hexylresorcinol only 29 % was 
excreted in urine and 67 % in faeces of dogs (Robbins 1931), which suggests only 20 to 30 % of the 
dose would be absorbed. The Panel noted that it was unlikely that absorption in the dog would differ 
from  other  species,  that,  based  on  biliary  excretion  thresholds,  the  faecal  material  in  dogs  was 
unlikely  to  be  biliary  excreted  material  and  that  the  amount  in  faeces  would  therefore  represent 
unabsorbed material. Furthermore the Panel noted that in addition to 4-HR (20-29 % in urine and 66-
67 % in faeces of human and dog (Robins1935) also provided excretion data on the more lipophilic 
heptylresorcinol (1 % in urine and 96 % in faeces). In addition data on the cresol series showed 
decreasing absorption with increasing chain length in dog following 1 g of compound orally; urinary 
excretion was 50 %, 11 % and 0 % for metacresol, hexyl(m)cresol and decyl(m)cresol, respectively 
(Robins  1935).  Taken  together  the  data  indicate  that  increasing the lipophilicity of such phenols 
decreases their excretion in urine and this probably reflects decreases in their absorption. Based on 
the above observations and considerations the Panel decided that read-across for ADME was not 
justified because of differences in the structure, physicochemical properties and biological behaviour 
of resorcinol and 4-HR. 
3.2.  Toxicological data 
3.2.1.  Acute oral toxicity 
Studies of acute oral toxicity of 4-HR indicated LD50 of approx. 750 mg/kg bw in albino rats (no 
further details) (Lamson et al. 1935), and of approx. 430 mg/kg bw in guinea pigs (no data about the 
sex) (Anderson et al. 1931). A single dose of 750 mg 4-HR/kg bw as 10 % solution in ethylene glycol 
was tolerated by 6 rabbits without severe effects (only weight loss and slight diarrhoea), whereas the 
same dose in crystalline form in gelatine capsules resulted in lethal effects all 6 animals within 5 days 
(Anderson et al. 1931). Re-evaluation of 4-hexylresorcinol (E 586) as a food additive  
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The  Panel  noted  that  4-HR  was  administered  in  ethylene  glycol  in  studies  in  rats  and  rabbits. 
Therefore the reported results could be confounded by the toxicity of the vehicle. 
3.2.2.  Short-term and subchronic toxicity 
Mice 
In a dose-range finding study groups of B6C3F1 mice (5/sex/group, 7-9 weeks of age) received 4-HR 
by gavage in corn oil at doses of 0 (vehicle control), 31.3, 62.5, 125, 250, or 500 mg/kg bw/day, 5 
days per week, during 16 days (NTP, 1988). Animals were observed twice daily and weighed on days 
1, 8 and 15. Necropsy was performed on all animals but histopathological examination was performed 
on a limited number of animals. Treatment with  4-HR did not affect the survival. No compound 
related clinical signs were observed. Final body weights of dosed and vehicle control mice were 
comparable. 
Groups of B6C3F1 mice (10/sex/group, 7-9 weeks of age) received 4-HR by gavage in corn oil at 
doses of 0 (vehicle control), 62.5, 125, 250, 500, or 1000 mg/kg bw/day, 5 days per week for 13 
weeks (NTP, 1988)). Animals were observed twice daily and weighed once a week. A necropsy was 
performed on all animals except those autolysed or cannibalised. All male mice and 9/10 females 
from a 1000 mg/kg bw/day group died during the first week of the study. No clinical signs of toxicity 
were  recorded  in  mice  surviving to the termination. Final  mean body weights of male mice that 
received 250 or 500 mg/kg bw/day were 6 % or 5 % lower than that of the vehicle controls. Final 
body weight of male mice treated with doses up to 125 mg/kg bw/day and of female mice receiving 
doses  up  to  500 mg/kg  bw  were  comparable  to  that  of  the  vehicle  controls.  Mild  to  moderate 
nephropathy was observed with incidences: 1/10; 4/10, 8/10, 7/10 in males and 0/10, 1/10, 7/10 and 
10/10  in  females  at  doses  of  4-HR  of  62,5,  125,  250  and  500 mg/kg  bw.  As  no  incidence  of 
nephropathy was mentioned in the report for the vehicle control, the Panel considered that this change 
was not recorded in this group (0/10). 
For the nephropathy in male mice the calculated accepted BMD10 values ranged from to 22 to 43 mg 
4-HR /kg bw/day. The BMDL10 values ranged from 7 to 21 mg 4-HR /kg bw/day. For the nephropathy 
in female mice the calculated accepted BMD10 values ranged from 30 to 138mg 4-HR/kg bw/day. The 
BMDL10 values ranged from 20 to 90 mg 4-HR /kg bw/day. 
Rats 
Groups of F344/N rats (5/sex/group, 5 weeks of age) received 4-HR by gavage in corn oil at doses of 
0 (vehicle control), 31.3, 62.5, 125, 250, or 500 mg/kg bw/day, 5 days per week, during 16 days (NTP, 
1988). Animals were observed twice daily and weighed on days 1, 8 and 15. Necropsy was performed 
on all animals but histopathological examination was performed on a limited number of animals. 
Treatment  with  4-HR  did  not  affect  the  survival.  No  clinical  signs  were  reported  except  for 
hyperexcitability in male rats from the 500 mg/kg bw/day group. Final mean body weights of male 
rats that received 250 or 500 mg/kg bw/day were 8 % or 16 % lower than that of the vehicle controls. 
Final  body  weight  of  male  rats  treated  with  doses  up  to  125 mg/kg  bw/day  and  of  female  rats 
receiving doses up to 500 mg/kg bw/day were comparable to that of the vehicle controls. According to 
the Panel the NOAEL was 125 mg/kg bw/day. 
Groups of F344/N rats (10/sex/group, 4 weeks of age) received 4-HR by gavage in corn oil at doses of 
0 (vehicle control), 62.5, 125, 250, 500, or 1000 mg/kg bw/day, 5 days per week, for 13 weeks (NTP, 
1988). Animals were observed twice daily for mortality, morbidity and clinical signs of toxicity and 
weighed  once  a  week.  A  necropsy  was  performed  on  all  animals  except  those  autolysed  or 
cannibalised. All rats that received 1000 mg/kg bw/day of 4-HR died during the first week of the 
study. Final mean body weights of rats that received 250 or 500 were 22 % or 38 % lower than that of 
the vehicle control males and 16 % or 9 % lower for females. Clinical signs of toxicity included nasal 
discharge, ocular irritation, alopecia, diarrhoea, and cachexia. At necropsy, reduction in the size of the Re-evaluation of 4-hexylresorcinol (E 586) as a food additive  
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seminal vesicles was seen in 1/10 males at 250 mg/kg bw/day, 6/10 at 500 mg/kg bw/day, and in 4/10 
males at 1000 mg/kg bw/day. Histopathological changes reported were: hypospermatogenesis in 4/10 
males at 1000 mg/kg bw/day and hypoplasia of seminal vesicles in 3/10 males at 500 mg/kg bw/day 
and 5/10 males at 1000 mg/kg bw/day. According to the Panel the NOAEL was 125 mg/kg bw/day. 
In  summary  of  short-term  and  subchronic  toxicity  studies  in  rodents  no  signs  of  toxicity  were 
recorded in mice after administration of 4-HR in doses amounting to 1000 mg/kg bw/day. In a 13-
week study in mice, mild to moderate nephropathy, the incidence of which appeared dose related, was 
reported for males from 65 mg/kg bw/day and for females from 125 mg/kg bw/day. For nephropathy 
in the male mice the BMDL10 values ranged from 7 to 21 mg 4-HR /kg bw/day and in female mice the 
BMDL10 values ranged from 20 to 90 mg 4-HR /kg bw/day. 
In short-term and subchronic toxicity studies in rats by NTP a NOAEL was 125 mg 4-HR/kg bw/day 
based on reduction of body weight observed from 250 mg 4-HR/kg bw/day in males in the 16-day 
study, and in both sexes in the 13-week study. Other clinical symptoms included hyper-excitability (at 
at the top dose of 500 mg/4-HR/kg bw/day for 16 days) or nasal discharge, ocular irritation, alopecia, 
diarrhoea, and cachexia (no data about dose; 13-week study). At doses associated with reduction of 
body  weight  in  the  13-week  study  adverse  effects  on  morphology  or  function  of  male  reductive 
system were seen: reduction of the size of seminal vesicles (from 250 mg/kg bw/day), hypoplasia of 
seminal vesicles (from 500 mg/kg bw/day), and hypospermatogenesis at a high dose associated with 
mortality (at 1000 mg/kg bw/day). At that dose all male and female rats died during the first week of 
treatment. 
The  Panel  noted  that  in  short-term  and  subchronic  toxicity  studies  by  NTP  (1988)  haematology, 
clinical chemistry and urinalysis were not performed and the organ weights were not recorded. 
3.2.3.  Genotoxicity 
The results of in vitro genotoxicity studies on 4-HR are summarized in Table 6. 
Table 6: Genotoxicity of 4-HR in vitro 
Endpoint & 
Test system 
Tested 
organisms 
Tested con-
centrations & 
vehicle 
Cytotoxic 
concentration 
Results 
-MA
(a) 
Results 
+MA  Validity  Reference 
Gene mutation  
Ames test 
S. Typhimurium 
TA98, TA100, 
TA1535, 
TA1537, 
TA1538 
5-30 
µg/plate in 
DMSO 
No data but 
tested up to 
precipitation 
threshold 
Nega-
tive 
Nega-
tive 
Suffi-
cient
(b) 
Cortinas de 
Nava et al., 
1983 
Ames test 
S. Typhimurium 
TA98, TA100, 
TA1535, TA1537 
1-333 
µg/plate in 
95 % ethanol 
Tested up to 
cytotoxic 
dose levels in 
each strain  
Nega-
tive 
Nega-
tive 
Suffi-
cient
(b) 
NTP, 1988; 
Mortelmans et 
al., 1986 
Ames test 
S. Typhimurium 
TA98, TA100, 
TA1535, TA1537 
0.3-220 
µg/plate in 
DMSO 
Tested up to 
cytotoxic 
dose levels in 
each strain  
Nega-
tive 
Nega-
tive 
Suffi-
cient
(b) 
NTP, 1988; 
Mortelmans et 
al., 1986 
Ames test 
S. Typhimurium, 
TA100 
0.03-10 
µg/plate in 
DMSO 
No data 
Weak 
posi-
tive 
Not 
tested 
Insuffi-
cient 
Il‟inskaya et 
al., 2002 Re-evaluation of 4-hexylresorcinol (E 586) as a food additive  
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Endpoint & 
Test system 
Tested 
organisms 
Tested con-
centrations & 
vehicle 
Cytotoxic 
concentration 
Results 
-MA
(a) 
Results 
+MA  Validity  Reference 
Mouse 
lymphoma 
assay 
L5178Y cells 
1.25-40 
µg/mL in 
medium 
Tested up to 
cytotoxic 
dose levels  
Nega-
tive 
Posi-
tive
(e) 
Suffi-
cient 
NTP, 1988; 
Myhr et al., 
1990 
Chromosome mutation 
Chromo-
some 
aberration 
test 
Chinese 
hamster ovary 
cells 
5, 16, 50 (-
MA) or 1, 5, 
16 µg/mL 
(+MA) in 
DMSO 
Tested up to 
cytotoxic 
dose levels 
Nega-
tive 
Nega-
tive 
Suffi-
cient 
NTP, 1988; 
Anderson et 
al., 1990 
Cell transformation 
Cell  trans-
formation 
assay 
A31-1-13 
clone of 
BALB/c-3T3 
cells 
37-158 µM 
in medium 
(7-31 
µg/mL) 
Tested up to 
cytotoxic 
dose levels 
Nega-
tive
(d) 
No 
data 
Suffi-
cient 
Matthews, et 
al., 1993 
DNA damage 
Sister 
chromatid 
exchange 
(SCE) 
assay 
Chinese 
hamster ovary 
cells 
16, 18, 20 (-
MA) or 5, 
16, 50 
µg/mL 
(+MA) in 
DMSO 
Tested up to 
cytotoxic 
dose levels 
Posi-
tive 
Nega-
tive 
Suffi-
cient 
NTP, 1988; 
Anderson et 
al., 1990 
pol A 
liquid 
suspension 
assay 
E. coli pol A+ 
or pol A- 
4-16 
µg/plate in 
medium 
Not 
applicable 
(survival 
index 
determined) 
Posi-
tive
(c) 
No 
data 
No 
vali-
dated 
test 
system 
Espinosa-
Aguirre et al., 
1987 
SOS 
chromo test 
E. coli 
PQ37sfiA::lac
Z 
10, 50, 100 
µg/mL in 
DMSO 
No data  Posi-
tive 
No 
data 
No 
vali-
dated 
test 
system 
Margulis et 
al., 2003 
(a):  Metabolic activation system 
(b):  but not tested in TA102 or E. coli WP2  
(c):  positive also in the disc diffusion assay but negative in the micro-suspension assay with and without MA using the same 
test organisms 
(d):  sufficient  negative  transformation  response  in  the  first  experiment,  and  a  limited  activity  response  in  the  second 
experiment; authors summary: negative  
(e):  positive in 2 independent experiments, significant dose dependent increase in mutation frequency, app. doubling of 
concurrent control 
DMSO: dimethylsulphoxide 
__________________ 
Based  on  the  available  data,  4-HR  was not mutagenic in  S. Typhimurium strains TA98, TA100, 
TA1535, or TA1537 with or without metabolic activation, but TA 102 strain sensitive to oxidative 
damage was not tested. The test substance induced forward mutations at the TK locus in mouse 
L5178Y cells (small mutant colonies) in the presence but not in the absence of metabolic activation. 
Chromosomal aberrations were not induced in CHO cells with or without metabolic activation. 4-HR 
caused an increase in the frequency of sister chromatid exchanges (SCE) in the absence of metabolic 
activation; no increase of SCE was observed in the presence of S9. Pol A and SOS chromotests (not 
validated indicator tests) gave positive results for DNA damage in bacteria. 
In  vivo,  4-HR  was  tested  in  the  rat  liver  UDS  (unscheduled  DNA  synthesis)  assay  in  a  study 
performed under GLP compliance and according to OECD TG486. Male rats were gavaged with 600 
or 2000 mg 4-HR /kg bw. Corn oil was the vehicle. Hepatocytes were isolated from the livers 2 and 
14  hours  after  treatment.  No  significant  increases  in  UDS  were  noted,  but  no  proof  of  systemic 
exposure was provided (Huntingdon Life Sciences, 2001). The Panel noted that this test which is a Re-evaluation of 4-hexylresorcinol (E 586) as a food additive  
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reliable  but  weakly  sensitive  in  vivo  study  of  primary  DNA  damage  in  rat  liver  did  not  show 
genotoxic effects.  
Positive results were reported in a micronucleus test in vivo in mice (Margulis et al., 2005). In this 
study mice were i.p. injected with 0, 2.5, 5, 50, 500 mg/kg bw of 4-HR. Micronuclei were analysed in 
peripheral blood collected from caudal vein 24, 48, and 72 hours after the injection. The authors 
reported a dose-dependent genotoxic activity, pronounced in erythrocytes collected 24 hours after 
injection. However, the Panel noted several methodological shortcomings in this study (no data about 
number of animals per dose, clinical signs, and statistical analysis). Moreover, and most important, 
the  Panel  noted  that  the  authors  analysed  normochromatic  (mature)  erythrocytes  24  hours  after 
exposure: at this time no genetic effect induced in the target cell population before nucleus expulsion 
can be detected; thus the results lack biological plausibility and have to be considered as artefacts.  
Overall, the available data indicate that 4-HR is weakly genotoxic in some in vitro assays, with or 
without  metabolic  activation.  In  vivo  the  UDS  assay  in  rats  did  not  show  genotoxic  effects.  No 
adequate study on chromosomal damage in vivo was available. 
The Panel however noted the read across from genotoxicity data on resorcinol was scientifically 
justified, as the presence of an aliphatic chain in 4-HR is not expected to provide additional genotoxic 
potential  compared  to  resorcinol.  Based  on  the  extensive  genotoxicity  database  available  for 
resorcinol,  showing  positive  results  in  several  in  vitro  test  systems  and  negative  results  in  valid 
studies in vivo in rodents, the Panel previously concluded that resorcinol was not of concern with 
respect to genotoxicity (EFSA ANS Panel, 2010). Thus, based on the available experimental data on 
4-HR, considering the lack of structural alerts for genotoxicity in the molecule (Ashby and Tennant, 
1991), the genotoxic profile of resorcinol and the negative carcinogenicity studies in rodents, the 
Panel concluded that 4-HR does not raise concern for genotoxicity. 
3.2.4.  Chronic toxicity and carcinogenicity 
Studies in this section were available from the JECFA and SCF evaluations. Within the frame of the 
US National Toxicology Program a long-term toxicity and carcinogenicity study was performed in 
F344/N rats and B6C3F1 (NTP, 1988). Haematology, clinical chemistry, and urinalysis were not 
performed after 12 months. 
Mice 
Groups of B6C3F1 mice (50/sex/group, 7-8 weeks of age) were administered 0, 62.5, or 125 mg/kg 
bw 4-HR in corn oil by gavage 5 days per week for 102 weeks. (NTP, 1988). Necropsy was performed 
on  all  animals  except  excessively  autolysed  or  cannibalised  mice.  Complete  histopathological 
examination was performed on all high dose and vehicle control animals and on low dose animals 
dying  through  month  21  of  the  study.  Histopathological  examination of the low dose group was 
restricted to the adrenal glands, bone, kidneys, liver and lungs and Harderian glands in male and 
female mice The pituitary and thyroid glands were also examined in low dose females.  
No treatment-related clinical signs were noted and there was no significant difference in survival 
compared to controls. The mean body weights of males from the high- and low-dose groups were 9-
11 % and 6-8 % lower than controls, respectively. The mean body weights of low-dose females were 
6-16 % lower after week 67, and body weights of high-dose females were 4-10 % lower after week 
88. Nephropathy was reported by the authors to at increased incidences but no statistical analysis of 
the data was presented in the report (males: vehicle control, 39/50; low dose, 43/50; high dose, 47/50; 
females: 7/50; 40/49; 47/50). Nephropathy in male and female mice varied from mild focal atrophy of 
tubules in the outer cortex to severe atrophy with dilatation of the tubular lumens and Bowman‟s 
space, tubular cysts, tubular regeneration, and variable lymphoplasmocytic inflammatory infiltrates. 
The authors reported that the degree of severity of the nephropathy was judged to be greater in the Re-evaluation of 4-hexylresorcinol (E 586) as a food additive  
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treated  groups  compared  to  the  vehicle  control  groups.  Osteosclerosis  was  observed  at  increased 
incidences in the high dose male and female mice (males: vehicle control, 5/50; low dose, 5/50; high 
dose, 15/50; females: 21/50, 25/49; 40/50).  
Increased incidences of focal medullary hyperplasia of the adrenal gland were observed in male mice 
(5/50  in  control,  16/50  at  low  dose,  and  10/49  at  high  dose).  Pheochromocytomas in male mice 
occurred  with  a  marginal  upward  trend  (1/50;  2/50;  5/49).  The  incidences  of  neoplasms  of  the 
Harderian gland in male mice were slightly increased over those in controls (adenomas or carcinomas, 
combined: 0/50; 5/50; 3/50). Based on these data, the authors concluded that there was no evidence of 
carcinogenic activity in female mice but equivocal evidence of carcinogenic activity in male mice.  
In an evaluation by independent experts (Sauer, 1990; Environ, 1990, unpublished reports, cited in 
JECFA, 1996) the proliferative changes in the adrenal medulla were not considered to be treatment 
related since the incidences of phaeochromocytomas were within the historical control range and the 
statistical positive trend was borderline. Furthermore, the differentiation between focal hyperplasia 
and phaeochromocytoma was questionable and progression to malignancy was not dose dependent 
(occurred only at low dose). Concerning the Harderian gland neoplasm the re-evaluation has shown 
that  only  adenomas  were  diagnosed  but  no  carcinoma  (in  contrast,  6  out  of  8  neoplasm  were 
diagnosed  by  the  NTP  study  pathologist  as  carcinoma)  and  the  incidences  were  comparable  to 
historical controls.  
Based on the data in the NTP report and the re-evaluation (Sauer, 1990; Environ, 1990, unpublished 
reports, cited in JECFA, 1996) the Panel considered that no carcinogenic effect was detected in mice 
of either sex receiving doses amounting to 125 mg 4-HR/kg bw/day. However, the Panel noticed an 
increased incidence of osteosclerosis at the high dose and a dose dependent increase in the incidence 
of  nephropathy,  a  non-neoplastic  lesion,  which  was  also  reported  in  13-week  study.  The  Panel 
considered  both  changes  as  treatment-related.  With  regard  to  nephropathy  no  NOAEL  could  be 
identified and therefore the Panel calculated the Benchmark dose (Appendix A). In male mice the 
calculated accepted BMD10 values ranged from 11 to 13 mg 4-HR/kg bw/day. The BMDL10 values 
ranged from 6 to 8 mg 4-HR/kg bw/day. In female mice the calculated accepted BMD10 value was 4.6. 
 mg 4-HR/kg bw/day. The BMDL10 value was 4 mg 4-HR/kg bw/day. 
Rats 
Groups of F344/N rats (50/sex/group, 5-6 weeks of age) were administered 0, 62.5, or 125 mg 4-
HR/kg bw 4-HR in corn oil by gavage 5 days per week for 103 weeks (NTP, 1988). Necropsy was 
performed  on  all  animals  except  excessively  autolysed  or  cannibalised  rats.  Complete 
histopathological examination was performed on all high dose and vehicle control animals and on low 
dose animals dying through month 21 of the study. Histopathological examination of the low dose 
group was restricted to the adrenal glands, kidneys, liver, lungs and spleen in male rats and to kidneys, 
liver, lung and spleen female rats. 
No relevant clinical signs were observed. No effects on body weight were seen except in high dose 
male rats during the whole exposure period; the mean body weight in this group was 7-11 % lower 
than  the  control  value.  No  significant  effect  on  survival  was  reported  even  though  a  number  of 
females (3 control, 8 low-dose and 14 high-dose) died during the first year before they were at risk of 
developing tumours. No treatment-related neoplastic and non-neoplastic changes were observed in 
rats of either sex. The Panel considered that no carcinogenic effect was detected in rats of either sex 
receiving doses amounting to 125 mg 4-HR/kg bw/day. 
In summary, carcinogenicity studies in mice and rats demonstrated the lack of carcinogenic activity of 
4-HR  in  doses  amounting  to  125 mg/kg  bw/day.  In  treated  mice  of  both  sexes  the  incidence  of 
nephropathy was increased in a dose dependent manner compared to the controls. With regard to this 
finding no NOAEL could be identified in this study and the Panel calculated the Benchmark dose Re-evaluation of 4-hexylresorcinol (E 586) as a food additive  
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(Appendix A). In male mice the BMDL10 values ranged from 6 to 8 mg 4-HR/kg bw/day and in 
female mice the BMDL10 value was 4 mg 4-HR/kg bw/day. 
3.2.5.  Reproductive and developmental toxicity 
No data were available for the JECFA and SCF evaluations. No reproductive and developmental 
toxicity studies were found in the literature search.  
4-HR  has  been  found  to  be  a  spermicidal  agent  by  local  application  and  has  been  used  in 
contraceptive preparations, although it does not strip human spermatozoa completely (Brotherton, 
1977). 
3.2.6.  Other studies 
Studies  cited  in  this  section  and  published  before  1996  were  available  for  the  JECFA  and  SCF 
evaluations. Additional data were found in the literature search. 
Oestrogenic activity 
In a search for potential xenoestrogens among food additives 1500 compounds were analysed using in 
silico molecular modelling studies and  in vitro binding studies and assays in MCF-7 cells stably 
transfected  with  a  construct  encoding  luciferase  reporter    gene  under  control  of  an  oestrogen- 
responsive  promoter  (Amadasi  et  al.,  2009).  The  authors  reported  4-HR  to  act  as  a  potent 
transactivator in the nM range, without binding to the oestrogen receptor α (ERα) in the competition 
assay in vitro. The authors hypothesized that 4-HR had an indirect effect on the oestrogen receptor 
and facilitated the interaction between unliganded ER and coactivators.  
The Panel noted that the assays in MCF-7 human breast cancer cells are an in vitro model system to 
provide concentration response data for substances with in vitro ER agonist or antagonist activity. The 
Panel further noted that, the test methods used in the study, although widely used in the scientific 
community,  are  not  OECD  validated  methods,  in  contrast  to  the  BG1Luc  oestrogen  receptor 
transcriptional activation (TA) test method for identifying  ER  agonists and antagonist. This test 
method utilises an ER responsive (ERα and weakly expressing ERβ) human ovarian adenocarcinoma 
BG1  Luc  cell  line  stably  transfected  with  a  luciferase  reporter  gene  under  the  control  of  four 
oestrogen response elements upstream of the mouse mammary tumor virus promoter (OECD TG 457 
or OECD TG 455).  
Sensitisation 
In  a  study  on  delayed  contact  sensitization  in  male  Hartley  guinea-pigs  4-HR  did  not  induce 
sensitisation  after  dermal  exposure  via  “5-daily  applications”  or  s.c.  injection  of  an  emulsion  in 
complete Freund's adjuvant, at weekly intervals no data about dose (Baer et al., 1966).  
Although  4-HR  has  been  used  in  therapeutic  products  for  decades  no  allergenic  or  intolerance 
reactions have been reported in humans after oral administration (Frankos et al., 1991). 
A female patient with contact dermatitis following repeated occupational exposure to 4-HR reacted 
strongly in a patch test 48 and 72 hours after dermal exposure to 4-HR at a concentration of 0.1 % in 
petrolatum (pet). Negative results were obtained in 20 controls. Same results were reported in a repeat 
trial. The patient did not cross-react with 2 % resorcinol (Burrows & Irvine, 1982). 
In patients with resorcinol induced dermatitis the cross-reactivity was tested in patch tests; 2 out of 8 
subjects reacted positively to  4-HR, 3 responded with slight irritation and 3 were negative (Keil, 
1962, cited in JECFA, 1996). Re-evaluation of 4-hexylresorcinol (E 586) as a food additive  
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4.  DISCUSSION 
The Panel was not provided with a newly submitted dossier and no new toxicological or biological 
information was submitted for the present re-evaluation  following a public call for data and based its 
evaluation on previous evaluations and additional literature that became available since then. The 
Panel noted that not all original studies on which previous evaluations were based were available for 
re-evaluation. 
4-HR (E 586) is an  antioxidant authorised as a food additive in the EU to prevent melanosis in 
shrimps and related crustaceans that was previously evaluated for this specific use only by the EU 
SCF in 2003 and the JECFA in 1996. 
The SCF concluded that the available data did not allow the establishment of an ADI but the use was 
considered  as  toxicologically  acceptable  under  the  conditions  described  provided  residues  in 
crustacean meat did not exceed 2 mg/kg.  
JECFA,  based  on  the  available  data  in  animals,  was  unable  to  establish  a  numerical  ADI  but 
concluded that the treatment of crustaceans at concentrations of up to 50 mg/L resulting in residue 
levels of approximately 1 mg/kg in the edible portion was not of toxicological concern. According to 
JECFA “for more extensive use or higher levels of application, further toxicological data would be 
required, including a long-term toxicity study in mice that establishes a clear NOEL and the results of 
reproductive toxicity/teratogenicity studies”. 
Specifications have been defined in the Commission Regulation (EU) No 231/2012 and by JECFA 
(2006). The purity is specified to be not less than 98 %. 
Excretion of unlabelled 4-HR after oral application was measured in human subjects and male dogs 
(Robbins 1935, 1931). Following oral administration of 1 g 4-HR about 18 % was recovered in the 
urine and 64  % in faeces in humans (Robbins, 1935) and about 29  % in urine and 67  % in faeces of 
dogs (Robbins, 1931) These studies provided an indication for absorption from the gastro-intestinal 
tract reaching a rate of 20-30 % of the applied dose. Data on metabolites were sparse. There was an 
indication  for  excretion  of  conjugates  of  4-HR  via  urine  in  the  dog.  The  Panel  noted  several 
limitations in the studies by Robbins (1931,1935): (a) the colorimetric method for the estimation of 
phenolic compounds in the urine and faeces provided a rough quantification without differentiation 
between unchanged 4-HR and metabolites, (b) data on amounts detected in faeces did not distinguish 
between  unabsorbed  compound  and  absorption  followed  by  excretion  via  bile,  (c)  excretion  via 
exhalation of metabolites was not considered and (d) distribution and retention in the body was not 
accounted for. The Panel further noted the lack of ADME studies in the rat, the species on which the 
toxicological studies were performed.  
Although  the  studies  on  acute  oral  toxicity  did  not  correspond  to  current  guidelines,  they  were 
considered sufficient for evaluation of this endpoint. Oral LD50 was 750 mg 4-HR/kg bw in rats and 
430 mg 4-HR/kg bw in guinea pigs. 
Subchronic studies in rats and mice were available (NTP,1988).  
In  mice  no  signs  of  toxicity  were  recorded  in  a  16-day  study  with  4-HR  in  doses amounting to 
500 mg/kg bw/day. In a 13-week study in mice mortality occurred in the highest dose (1000 mg/kg 
bw/day, all males and 9/10 females). Furthermore, mild to moderate nephropathy, the incidence of 
which appeared dose-related, was reported for males from 65 mg/kg bw/day and for females from 
125 mg/kg  bw/day.  With  regard  to  nephropathy  no  NOAEL  could  be  identified  and  the  Panel 
calculated the Benchmark dose. The BMDL10 values ranged from 7 to 21 mg 4-HR/kg bw/day for 
males and from 20 to 90 mg 4-HR/kg bw/day for females. Re-evaluation of 4-hexylresorcinol (E 586) as a food additive  
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In rats hyper-excitability at the top dose of 500 mg 4-HR/kg bw/day in the 16 day study, or nasal 
discharge, ocular irritation, alopecia, diarrhoea, and cachexia (no data about dose) in the 13-week 
study were reported. A reduction in body weight was observed from 250 mg 4-HR/kg bw/day in males 
in the 16-day study, and in both sexes in the 13 week study. At doses associated with reduction of 
body weight in a 13-week study adverse effects on morphology or function of male reductive system 
were seen: reduction of the size of seminal vesicles (from 250 mg/kg bw/day), hypoplasia of seminal 
vesicles (from 500 mg/kg bw/day), and hypospermatogenesis at a high dose (1000 mg/kg bw/day) 
associated  with  mortality.  At  that  dose  all  male  and  female  rats  died  during  the  first  week  of 
treatment. 
The available genotoxicity data indicated that 4-HR was weakly genotoxic in some in vitro assays, 
with or without metabolic activation. In vivo the UDS assay in rats did not show genotoxic effects. No 
adequate study on chromosomal damage in vivo was available. The Panel however noted the read-
across from genotoxicity data on resorcinol was scientifically justified, as the presence of an aliphatic 
chain in 4-HR is not expected to provide additional genotoxic properties compared to resorcinol. 
Based on the extensive genotoxicity database available for resorcinol, showing positive results in 
several  in  vitro  test  systems  and  negative  results  in  valid  studies  in  vivo  in  rodents,  the  Panel 
previously concluded that resorcinol was not of concern with respect to genotoxicity (EFSA ANS 
Panel,  2010).  Thus,  based  on  the  available  experimental  data  on  4-HR,  considering  the  lack  of 
structural alerts for genotoxicity in the molecule (Ashby and Tennant, 1991) and the genotoxic profile 
of resorcinol, the Panel concluded that 4-HR does not raise concern for genotoxicity. 
Carcinogenicity  studies  performed  by  NTP  (NTP,  1988)  in  B6C3F1  mice  and  F344/N  rats 
demonstrated the lack of carcinogenic activity of 4-HR in doses amounting to 125 mg/kg bw/day. In 
treated mice of both sexes osteosclerosis was observed at increased incidences in the high dose group 
and incidence of nephropaty, a non-neoplastic lesion, which was also reported in the 13-week-study, 
was  increased  in  a  dose  dependent  manner.  With  regard  to  nephropathy  no  NOAEL  could  be 
identified and the Panel calculated the Benchmark dose. In male mice the BMDL10 values ranged 
from 6 to 8 mg 4-HR/kg bw/day and in female mice the BMDL10 value was 4 mg 4-HR/kg bw/day. 
Studies on reproductive and developmental toxicity were not available. 4-HR has been found to be a 
spermicidal agent by local application and has been used in contraceptive preparations, although it 
does not strip human spermatozoa completely (Brotherton, 1977).  
Oestrogenic activity of 4-HR was demonstrated in an in vitro model system (Amadasi et al., 2009). 
According to EFSA‟s Scientific Opinion on the hazard assessment of endocrine disruptors (EFSA 
Scientific Committee, 2013) “the fact that a substance in an in vitro assay is binding to an endocrine 
receptor, then interfering with the intracellular messenger system connecting receptor to target or 
resulting in an endocrine related response in a target cell must be taken as strong indication for 
endocrine activity. If a suitable animal model provides further indication for an endocrine-related 
adverse effect, this substance should be considered an endocrine disruptor”. Whether the in vitro 
oestrogenic activity of 4-HR is associated with an adverse effect in an intact organism remains to be 
investigated. The Panel considered that the significance of these in vitro findings for risk assessment 
of 4-HR is difficult to be ascertained in absence of additional studies in vivo. The Panel considers that 
in light of the limitation of reproductive toxicity database any potential adverse effects due to the 
oestrogenic activity of 4-HR in vivo might be further explored to reduce this uncertainty. 
Human studies have pointed to the possibility of contact dermatitis in persons who are allergic to 
resorcinol. 
The calculation of exposure was based on the MPLs defined as a residue level of 2 mg 4-HR/kg 
permitted  in  crustaceans  according  to  the  to  the  Annex  II  of  Regulation  (EC)  No 1333/2008. 
However, there was no information on the actual practice of treating shrimps with 4-HR on ships or Re-evaluation of 4-hexylresorcinol (E 586) as a food additive  
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after landing and no data on residual levels of 4-HR in shrimps on the market were available for the 
Panel. The only available data on residual levels were from experiments at a laboratory level on the 
treatment of shrimps, reported in literature. These analyses were done under conditions that might not 
be really comparable between publications and/or in practice considering e.g. different concentrations 
of 4-HR in the dipping solutions, different dipping times applied, storage of shrimps whether or not 
under refrigerated conditions, heat treatment of shrimps before or after treatment. Therefore, it was 
not  clear  for  the  Panel  whether  the  level  of  1.2 mg  4-HR/kg  shrimps  as  used  for  the  exposure 
calculations did really reflect the residue levels of 4-HR in shrimps on the market. Therefore the Panel 
decided that this value should not be used for the risk characterization until further information on the 
residue levels in shrimps on the market become available. This decision was supported by Montero et 
al. (2006) who stated that it was difficult to reduce the 4-HR levels to acceptable values below the 
maximum limit, due to the influence of different processing technologies. 
 
To be in line with the Food Additive Intake Model (FAIM) as used by EFSA, exposure was initially 
calculated for the consumption of the food group “unprocessed fish and fisheries products”. Because 
this would result in an overestimation due to the fact that foods other than crustaceans were included 
in  the  group  the  exposure was calculated based on the consumption of  crustaceans only directly 
obtained from the Comprehensive Database. 
When  considering  MPLs  defined  as  residue  of  2  mg  4-HR/kg  crustacean  meat  mean  exposure 
estimates from crustaceans‟ consumption range between 0.0 and 0.2 µg/kg bw/day for all population 
groups. High level exposures are estimated to be in the range of 0.0 – 1, 0.0 -2.5, 0.0 – 1.6, 0.5 – 3.3 
and 0.1 – 1.2 µg/kg bw/day, respectively for toddlers, children, adolescents, adults and the elderly 
(Table 5). When considering use levels reported from the literature, mean exposure estimates from 
crustaceans‟ consumption range between 0.0 - <0.05, 0.0 – 0.1, 0.0 – 0.1, <0.05 – 0.1, and <0.05– 
0.05 µg/kg bw/day, respectively for toddlers, children, adolescents, adults and the elderly. High level 
exposures for these population groups were estimated to be in the range of 0.0 – 0.6, 0.0 -1.5, 0.0 – 
1.0, 0.3 – 2.0 and 0.1 – 0.7 µg/kg bw/day, respectively (Table 5). 
From the highest consumption level (95
th percentile of consumers only) of crustaceans, the highest 
exposure estimate of 3.3 µg/kg bw/day for adults calculated using MPLs defined as residue of 2 mg 4-
HR/kg crustacean meat, would result in  MoS of 1200 when compared to the lowest BMDL10 of 
4 mg/kg bw/day in the carcinogenicity study in female mice (NTP, 1988). 
The Panel agreed with the SCF that the database did not allow the establishment of an ADI due to the 
limitation of the biological and toxicological database, which included the lack of ADME studies in 
the  rat,  the  species  in  which  the  available  toxicological  studies  were  performed,  and  of  the 
reproductive and developmental toxicity studies as well as the inability to read-across of these data 
from resorcinol to 4-HR due to differences between the compounds in the structure, physiochemical 
properties and biological behaviour.  
However, considering that  
  4-HR is only permitted as a food additive for a specified use in crustaceans,  
  the  BMDL10  values  identified  by  the  Panel  were  based  on  the  most  sensitive  endpoint 
(nephropathy),  
  the MoS between the lowest BMDL10 in female mice from the carcinogenicity study was 
1200 and 
  the highest exposure estimate based on MPL defined as residue of 2 mg 4-HR/kg was 3.3 
µg/kg bw/day  Re-evaluation of 4-hexylresorcinol (E 586) as a food additive  
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the Panel concluded that, at the currently permitted use and use levels (as residue), 4-HR as food 
additive is not of safety concern. 
The Panel considered that any increase in the permitted use levels and/or extension of the uses to 
other food categories would require additional investigations in vivo such as extended one-generation 
reproductive toxicity study (OECD TG No. 443)  
CONCLUSIONS AND RECOMMENDATIONS 
4-HR  was  evaluated  by  the  EU  Scientific  Committee  for  Food  (SCF)  in  2003  and  the  Joint 
FAO/WHO Expert Committee on Food Additives (JECFA) in 1996 as food additive for prevention of 
development  of  melanosis  in  shrimps  and  related  crustaceans.  Both  Committees  recognised  that 
available  database  was  not  sufficient  to  establish  an  ADI  but  considered  4-HR  toxicologically 
acceptable for prevention of melanosis in shrimps under conditions provided residues in crustacean 
meat did not exceed 2 mg/kg (SCF) or 1 mg/kg (JECFA).  
The Panel concluded that the present database does not justify revision of the SCF‟s evaluation. The 
Panel agreed with the SCF that the database does not allow the establishment of an ADI.  
The Panel concluded that the MoS value calculated by the Panel was sufficient given the conservative 
nature  of  exposure  estimates  and  limited  uses.  Accordingly  the  Panel  concluded  that  4-HR  was 
toxicologically acceptable for prevention of melanosis in shrimps and related crustaceans provided 
residues in crustacean meat do not exceed 2 mg/kg. The Panel concluded that any increase in the 
permitted use would require additional reproductive toxicity studies. 
The  Panel  noted  that  the  information  on  actual  residual  levels  in  crustaceans  was  limited  and 
recommends monitoring of these levels in the European market. 
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Appendix A.   Benchmark  dose  and  margin  of  safety  calculation  in  re-evaluation  of  4-HR 
(E 586) 
Benchmark dose calculation 
In the 13-week study and carcinogenicity study in mice (NTP 1988) nephropathy was considered by 
the Panel as the most sensitive effect of 4-HR toxicity. 
Benchmark dose (BMDL10) was calculated using the US EPA‟s benchmark dose software, BMDS 
version 2.4. All models for dichotomous (quantal) data were selected for the analysis at the default 
benchmark response (BMR) of 10% (95% confidence level) advised by the EFSA guidance on the use 
of benchmark dose (EFSA Scientific Committee, 2009). 
Model acceptability criteria were as follows: All quantal dose response models in the US EPA‟s 
benchmark dose software, BMDS version 2.4 were used. In accordance with the EFSA guidance 
(EFSA Scientific Committe, 2009) a goodness-of-fit was judged as sufficient if the fit showed a p-
value not smaller than 0.05 ( i.e. p≥0.05), using the likelihood ratio test. 
Table 1:  Results of a BMD analysis of the data on incidence of nephropathy reported in the 13-
week study in male mice (NTP, 1988). 
Model name  AIC  P-value  Accept  BMD10*  BMDL10* 
Logistic  56.1125  0.034  No  79.8759  55.1711 
LogLogistic  49.0117  0.4258  Yes  40.4049  6.79766 
LogProbit  49.0594  0.4228  Yes  42.9632  8.06187 
Multistage  49.3658  0.4256  Yes  21.9203  12.317 
Multistage-Cancer  48.0431  0.4436  Yes  29.9853  20.7047 
Probit  56.0707  0.0351  No  78.7799  56.5566 
Weibull  48.0431  0.4436  Yes  29.9853  20.7047 
Quantal-Linear  48.0431  0.4436  Yes  29.9853  20.7047 
*:  For  the calculations using the BMDS v. 2.4 the actual doses of 4-HR reported in the study were multiplied by 10. 
Respectively, the results obtained for BMD10 and BMDL10 were divided by 10, and as such are presented in the Table. 
For the nephropathy in the 13-week study in male mice the calculated accepted BMD10 values ranged 
from 22 to 43 mg 4-HR/kg bw/day. The BMDL10 values ranged from 7 to 21 mg 4-HR/kg bw/day. 
 
Table 2: Results of a BMD analysis of the data on incidence of nephropathy reported in the 13-week 
study in female mice (NTP, 1988). 
Model name  AIC  P-value  Accept  BMD10*  BMDL10* 
Gamma  22.8072  0.9969  Yes  127.824  83.0816 
Logistic  23.1606  0.9632  Yes  138.336  89.9401 
LogLogistic  23.1056  0.9714  Yes  130.772  87.6795 
LogProbit  22.8835  0.9917  Yes  127.802  87.8678 
Multistage  20.4252  0.2745  Yes  131.868  - 
Multistage-Cancer  23,5557  0.7571  Yes  81.8176  52.7611 
Probit  22.9538  0.9858  Yes  132.764  85.087 
Weibull  22.8762  0.993  Yes  129.99  77.7036 
Quantal-Linear  32.9426  0.0938  Yes  29.8943  20.0092 
*: For the calculations using the BMDS v. 2.4 the actual doses of 4-HR reported in the study were multiplied by 10. 
Respectively, the results obtained for BMD10 and BMDL10 were divided by 10, and as such are presented in the Table. 
-: no BMDL10 was calculated for this model. 
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For the nephropathy in the 13-week study in female mice the calculated accepted BMD10 values 
ranged from 30 to 138 mg 4-HR/kg bw/day. The BMDL10 values ranged from 20 to 90 mg 4-HR/kg 
bw/day. 
Table  3:  Results  of  a  BMD  analysis  of  the  data  on  incidence  of  nephropathy  reported  in  the 
carcinogenicity study in male mice (NTP, 1988). 
Model name  AIC  P-value  Accept  BMD10*  BMDL10* 
Gamma  121.884  NA  -  26.5222  - 
Logistic  120.015  0.7164  Yes  11.8945  7.1241 
LogLogistic  121.884  NA  -  29.9132  - 
LogProbit  121.884  NA  -  31.7203  - 
Multistage  121.884  NA  -  20.6099  3.82435 
Multistage-Cancer  121.884  NA    20.6099  6.23545 
Probit  119.972  0.7656  Yes  12.7099  8.03126 
Weibull  121.884  NA  -  24.0281  6.23545 
Quantal-Linear  120.061  0.673  Yes  10.9673  6.13823 
*: For the calculations using the BMDS v. 2.4 the actual doses of 4-HR reported in the study were multiplied by 10. 
Respectively, the results obtained for BMD10 and BMDL10 were divided by 10, and as such are presented in the Table. 
NA: not analysed. 
-: no BMDL10 was calculated for this model. 
 
For the nephropathy in the carcinogenicity study in male mice the calculated accepted BMD10 values 
ranged from 11 to 13 mg 4-HR/kg bw/day. The BMDL10 values ranged from 6 to 8 mg 4-HR/kg 
bw/day. 
Table  4:  Results  of  a  BMD  analysis  of  the  data  on  incidence  of  nephropathy  reported  in  the 
carcinogenicity study in female mice (NTP, 1988). 
Model name  AIC  P-value  Accept  BMD10*  BMDL10* 
Gamma  115.931  NA  -  1,17451  0.731E-24 
Logistic  117.715  0.036  No  1.17285  9.11361 
LogLogistic  115.931  NA  -  9.48192  0.0000149795 
LogProbit  115.931  NA  -  7.61415  0.372E-05 
Multistage  115.931  NA  -  3.7771  2.25183 
Multistage-Cancer  114.194  0.6033  Yes  4.5774  3.60375 
Probit  119.778  0.0117  No  11.7361  9.5335 
Weibull  114.194  0.6033  Yes  4.5774  3.60375 
Quantal-Linear  114.194  0.6033  Yes  4.5774  3.60375 
*: For the calculations using the BMDS v. 2.4 the actual doses of 4-HR reported in the study were multiplied by 10. 
Respectively, the results obtained for BMD10 and BMDL10 were divided by 10, and as such are presented in the Table. 
NA: not analysed. 
-: no BMDL10 was calculated for this model. 
 
For the nephropathy in the carcinogenicity study in female mice the calculated accepted BMD10 
value was 5 mg 4-HR/kg bw/day. The BMDL10 value was 4 mg 4-HR/kg bw/day. Re-evaluation of 4-hexylresorcinol (E 586) as a food additive  
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Calculation of margin of safety (MoS) 
In order to be prudent the ANS Panel used the lowest BMDL10 value among the accepted ones for the 
calculation of MoS. Thus BMDL10 of 4 mg 4-HR/kg bw/day with regard to nephropathy in female 
mice in the carcinogenicity study by NTP (1988) was used. 
From the highest consumption level (95th percentile of consumers only) of “crustaceans”, the highest 
exposure estimate of 3.3 µg/kg bw/day for adults calculated using MPLs defined as residue of 2 
mg/kg crustacean meat (Table 5 in the opinion), would result in MoS of 1200 when compared to the 
lowest BMDL10 of 4 mg/kg bw/day in the carcinogenicity study in female mice (NTP, 1988). 
The Panel noted that it was not clear for the Panel whether the level of 1.2 mg 4-HR/kg shrimps, 
reported from the literature, as used for the refined exposure calculations did really reflect the residue 
levels of 4-HR in shrimps on the European market. Therefore the Panel decided that this value should 
not be used for the risk characterization until further information on the residue levels in shrimps on 
the European market become available. This issue is also discussed in the opinion on the re-evaluation 
of 4-HR (E 586) by the ANS Panel (section 4. Discussion). 
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ABBREVIATIONS 
ADI  Acceptable Daily Intake 
CAS  Chemical Abstracts Service 
DNA  Deoxyribonucleic acic 
EC  European Commission 
EFSA  European Food Safety Authority 
EINECS   European Inventory of Existing Commercial Chemical Substances 
EU  European Union 
FAO/WHO  Food  and  Agriculture  Organization  of  the  United  Nations/Word  Health 
Organization 
FDA  Food and Drug Administration 
GRAS  Generally Recognised As Safe 
HPLC  High-performance liquid chromatography 
JECFA  Joint FAO/WHO Expert Committee on Food Additives 
LD50  Lethal Dose, 50% i.e. dose that causes death among 50% of treated animals 
NOAEL   No-Observed-Adverse-Effect Level 
NOEL   No-Observed-Effect Level 
NEL  No-Effect Level 
PPO  Polyphenol Oxidase  
SCF  Scientific Committee for Food 
UDS  Unscheduled DNA Synthesis  
NTP  National Toxicology Program 
OECD  Organisation for Economic Co-operation and Development 
 